Free tool
Rare disease stocks
We cover 12 companies grouped under the Rare disease theme. The median market value in the group is $11.51B. Across the group, the median move over the past trading day is +0.16%. Price change over the past year runs from −14.4% to +48.4% across the middle 80 percent of the group, with a median of +7.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
12 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | $140.77B | Large cap | +40.14% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $112.52B | Large cap | +42.39% |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $35.05B | Large cap | −46.85% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | $31.87B | Large cap | −11.75% |
| 0JAV.L | Insmed Incorporated | $12.89B | Large cap | −6.25% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.60B | Large cap | +2.09% |
| ABVX.PA | ABIVAX Société Anonyme | $10.42B | Large cap | +42.59% |
| 0JDI.L | Ionis Pharmaceuticals, Inc. | $10.40B | Large cap | +49.07% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +12.68% |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $6.98B | Mid cap | +317.86% |
| CAMX.ST | Camurus AB (publ) | $3.87B | Mid cap | −14.52% |
| 0RD1.L | Camurus AB (publ) | $2.84B | Mid cap | −13.50% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.